These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime--a population study in 25 elderly patients. Urien S; Laurent N; Barre J; Druguet M; Bouvier D'yvoire M; Maire P Eur J Clin Pharmacol; 2004 Mar; 60(1):11-6. PubMed ID: 14767629 [TBL] [Abstract][Full Text] [Related]
5. Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime. Neu HC Rev Infect Dis; 1982; 4 Suppl():S374-8. PubMed ID: 6294786 [TBL] [Abstract][Full Text] [Related]
6. Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review. Jones RN Diagn Microbiol Infect Dis; 1995; 22(1-2):19-33. PubMed ID: 7587039 [TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum. Jones RN; Barry AL Antimicrob Agents Chemother; 1987 May; 31(5):818-20. PubMed ID: 3606081 [TBL] [Abstract][Full Text] [Related]
8. Prevention of intracranial problems in ear and sinus surgery: a possible role for cefotaxime. Weiner GM; Williams B J Laryngol Otol; 1993 Nov; 107(11):1005-7. PubMed ID: 7904618 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of cefotaxime in combination with metronidazole for empirical treatment of brain abscess in clinical practice: a retrospective study of 66 consecutive cases. Jansson AK; Enblad P; Sjölin J Eur J Clin Microbiol Infect Dis; 2004 Jan; 23(1):7-14. PubMed ID: 14669073 [TBL] [Abstract][Full Text] [Related]
10. Cefotaxime in brain abscesses. Martin Luengo F; Poza M; Pérez-Espejo MA; Gómez J Infection; 1986; 14(2):89-90. PubMed ID: 3710598 [No Abstract] [Full Text] [Related]
11. The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria. Devlin HR; Boskovski L Drugs; 1988; 35 Suppl 2():45-50. PubMed ID: 3396488 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime. Oizumi K; Hayashi I; Aonuma S; Konno K Drugs; 1988; 35 Suppl 2():57-61. PubMed ID: 3135170 [TBL] [Abstract][Full Text] [Related]
13. Brain abscess due to Capnocytophaga species, Actinomyces species, and Streptococcus intermedius in a patient with cyanotic congenital heart disease. Engelhardt K; Kampfl A; Spiegel M; Pfausler B; Hausdorfer H; Schmutzhard E Eur J Clin Microbiol Infect Dis; 2002 Mar; 21(3):236-7. PubMed ID: 11957031 [No Abstract] [Full Text] [Related]
14. Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism. Chin NX; Neu HC Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):21S-31S. PubMed ID: 6086215 [TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy. Jones RN; Barry AL; Thornsberry C Rev Infect Dis; 1982; 4 Suppl():S366-73. PubMed ID: 6294785 [TBL] [Abstract][Full Text] [Related]
16. Microbiology of cerebral abscess at the neurosurgical unit of the National Hospital of Sri Lanka. Seneviratne Rde S; Navasivayam P; Perera S; Wickremasinghe RS Ceylon Med J; 2003 Mar; 48(1):14-6. PubMed ID: 12795014 [TBL] [Abstract][Full Text] [Related]
17. Disposition of cefotaxime and its metabolite, desacetylcefotaxime, in rat: application of a pharmacokinetic-protein binding model. Hakim L; Bourne DW; Triggs EJ Xenobiotica; 1989 Jul; 19(7):743-54. PubMed ID: 2773510 [TBL] [Abstract][Full Text] [Related]
18. Pilot Study of the Pharmacokinetics of Cefotaxime in Critically Ill Patients with Acute Kidney Injury Treated with Continuous Renal Replacement Therapy. Koedijk JB; Valk-Swinkels CG; Rijpstra TA; Touw DJ; Mulder PG; van der Voort PH; van 't Veer NE; van der Meer NJ Antimicrob Agents Chemother; 2016 Jun; 60(6):3587-90. PubMed ID: 27021325 [TBL] [Abstract][Full Text] [Related]
19. Investigation of human bile and serum levels by high pressure liquid chromatography after administration of latamoxef or cefotaxime. Krausse R; Ullmann U; Brandstetter G; Kratochvil P Arzneimittelforschung; 1984; 34(12):1787-91. PubMed ID: 6099130 [TBL] [Abstract][Full Text] [Related]
20. Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling? Guerra Valero YC; Dorofaeff T; Coulthard MG; Sparkes L; Lipman J; Wallis SC; Roberts JA; Parker SL J Antimicrob Chemother; 2022 Jul; 77(8):2227-2237. PubMed ID: 35678266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]